Propanc Biopharma, Inc. (PPCB) Key Metrics
PPCB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.4M
- Enterprise value
- $2.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.1
- EV / EBITDA
- 2.9
- Dividend yield
- —
- Beta
- 3.33
PPCB key metrics, FY2017–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsPPCB returns How much profit the business earns on the capital it uses.
PPCB financial health Debt, liquidity and how easily interest is covered.
PPCB efficiency & capital use Working capital cycle and where the cash goes.
PPCB valuation history
PPCB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PPCB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PPCB cash returned to shareholders
PPCB price vs earnings per share
PPCB key metrics
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | — | $411.7M | — | — | — | — | — | — | — | — |
| Enterprise value | — | $413.4M | — | — | — | — | — | — | — | — |
| Price / book | — | 29.6 | — | — | — | — | — | — | — | — |
| Earnings yield | — | −14.3% | — | — | — | — | — | — | — | — |
| Free cash flow yield | — | −0.1% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.50 | $103.75 | $0.07 | $6.75 | $185.00 | $2,585.00 | $195,000.00 | $1,000,000.00 | $1,000,000.00 | $1,000,000.00 |
| Per share | ||||||||||
| Revenue per share | — | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | — | −$14.85 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | — | −$0.10 | — | — | — | — | — | — | — | — |
| Free cash flow per share | — | −$0.10 | — | — | — | — | — | — | — | — |
| Cash per share | — | $0.00 | — | — | — | — | — | — | — | — |
| Book value per share | — | $3.50 | — | — | — | — | — | — | — | — |
| Tangible book value per share | — | $3.50 | — | — | — | — | — | — | — | — |
| Capex per share | — | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | — | $0.44 | — | — | — | — | — | — | — | — |
| Shares outstanding | — | 4.0M | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −161.9% | — | — | — | — | — | — | — | — | — |
| Return on invested capital (ROIC) | −118.5% | −708.7% | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | −116.4% | −598.1% | — | — | — | — | — | — | — | — |
| Return on tangible assets | −147.6% | −300.1% | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $48,307 | $1.7M | $948,271 | $545,916 | $1.0M | $680,083 | $1.5M | $1.6M | $4.6M | $3.4M |
| Cash & short-term investments | $832,006 | $12,088 | $21,085 | $10,047 | $4,067 | $2,255 | $67,007 | $2,394 | $19,921 | $69,043 |
| Net debt | −$783,699 | $1.7M | $927,186 | $535,869 | $1.0M | $677,828 | $1.4M | $1.6M | $4.5M | $3.3M |
| Debt / equity | 0.01 | 0.12 | — | — | — | — | — | — | — | — |
| Debt / assets | 0.00 | 0.09 | 13.10 | 9.05 | 12.74 | 51.91 | 15.25 | 15.32 | 63.74 | 35.72 |
| Current ratio | 2.55 | 1.50 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 |
| Quick ratio | 2.55 | 1.50 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 |
| Interest coverage | -42.2 | -101.6 | -2.3 | -3.3 | -3.5 | -4.0 | -2.0 | -2.0 | -1.4 | -1.8 |
| Working capital | $5.2M | $2.8M | −$3.8M | −$3.1M | −$3.0M | −$3.1M | −$3.7M | −$4.3M | −$6.8M | −$5.5M |
| Invested capital | $8.6M | $15.6M | −$2.9M | −$2.6M | −$2.0M | −$2.4M | −$2.2M | −$2.7M | −$2.2M | −$2.1M |
| Tangible asset value | $9.4M | $13.9M | −$3.8M | −$3.1M | −$3.0M | −$3.1M | −$3.6M | −$4.3M | −$6.8M | −$5.4M |
| Net current asset value | $5.2M | $2.6M | −$3.8M | −$3.2M | −$3.1M | −$3.1M | −$3.7M | −$4.3M | −$6.8M | −$5.5M |
| Graham net-net per share | — | −$1.44 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | $932,246 | — | $192,960 | $466,273 | $700,340 | $391,749 | — | — | — | — |
| Share buybacks (net) | — | — | — | $590,250 | $766,500 | $776,044 | — | — | — | $0 |
| Capex / depreciation | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.25 | 978.72 | 0.00 |
| Efficiency | ||||||||||
| Days of inventory on hand | — | — | — | -58.9 | — | -28.2 | -401.5 | -860.9 | — | — |
| Days payables outstanding | 19,140.9 | — | 18,371.8 | 19,624.3 | 62,604.1 | 11,974.2 | 129,845.3 | 164,195.1 | 134,589.2 | 71,922.0 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.02 | — | 0.02 | 0.02 | 0.01 | 0.03 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $9,498 | $4,126 | $2,908 | $2,604 | $3,342 | $3,178 | $3,727 | $5,848 | $7,184 | $18,733 |
| Average payables | $1.2M | $1.2M | $1.1M | $954,870 | $972,679 | $922,246 | $879,746 | $1.0M | $820,441 | $426,803 |
| Average inventory | — | — | — | −$2,867 | — | −$2,172 | −$2,721 | −$5,439 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PPCB's annual financial statements (latest annual report filed September 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PPCB valuation and financial ratios
Propanc Biopharma earned a return on equity of −161.9% and a return on invested capital of −118.5% in fiscal 2026. It ended the year with $0.0 million of debt and $0.8 million in cash and short-term investments, a net cash position of $0.8 million. It returned $0.9 million to shareholders: $0.9 million in dividends and $0 in share buybacks.
See the PPCB income statement, the PPCB chart for price history, or the PPCB stock overview for the latest quote and news.
PPCB key metrics FAQ
What is Propanc Biopharma's return on equity?
Propanc Biopharma's return on equity (ROE) was −161.9% in fiscal 2026: net income of -$18.9 million on average shareholders' equity of $11.7 million.
What is Propanc Biopharma's ROIC?
Propanc Biopharma's return on invested capital was −118.5% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Propanc Biopharma have?
Propanc Biopharma had total debt of $0.0 million at the end of fiscal 2026, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Propanc Biopharma's current ratio?
Propanc Biopharma's current ratio was 2.55 at the end of fiscal 2026: current assets were 2.55 times current liabilities.